Who
Matthew Pauls
Director
Company insider
Files Form 4 as: Director, Pelthos Therapeutics; Director, Palvella Therapeutics; Director, Soleno Therapeutics; Chief Executive Officer, Savara; Director, Zyla Life Sciences; President & CEO, Strongbridge Biopharma; Chief Commercial Officer, Insmed.
In numbers
- Trades disclosed
- 88
- Buys
- 10
- Sells
- 6
- Bought
- $240K
- Sold
- $1.1M
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 1 Apr 2013
- Last trade
- 2 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Oct 2026filed 6 Oct 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $17K786 at $21.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $18K692 at $26.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $2,57294 at $27.36 | filing |
| 2 Jul 2026filed 7 Jul 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $18K692 at $26.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $2,57294 at $27.36 | filing |
| 29 Jun 2026filed 1 Jul 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 18 May 2026filed 18 May 2026 | Soleno TherapeuticsBiotechnology | SEC FORM 4 Code D | —10,491 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —9,063 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code D | —9,063 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeutics | SEC FORM 4 Code D | —10,491 | filing |
| 2 Apr 2026filed 6 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $8,514415 at $20.52 | filing |
| 2 Apr 2026filed 6 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $7,926371 at $21.36 | filing |
| 2 Apr 2026filed 6 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $8,516415 at $20.52 | filing |
| 2 Apr 2026filed 6 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $7,925371 at $21.36 | filing |
| 16 Dec 2025filed 16 Dec 2025 | SVRA SavaraBiotechnology | SEC FORM 4 Code G | —128,995 at $0.00 | filing |
| 14 Dec 2025filed 16 Dec 2025 | SVRA SavaraBiotechnology | SEC FORM 4 Code F | $1.4M195,705 at $6.92 | filing |
| 10 Dec 2025filed 12 Dec 2025 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Code G | —9,542 at $0.00 | filing |
| 10 Dec 2025filed 11 Dec 2025 | SVRA SavaraBiotechnology | SEC FORM 4 Code G | —23,629 at $0.00 | filing |
| 2 Oct 2025filed 12 Dec 2025 | PTHS Pelthos Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,123 at $0.00 | filing |
News
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Downgraded by Zacks Research to Strong SellPTHS · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Matthew Pauls; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.